MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1245/s10434-025-17809-5

Медицинская библиотека · Annals of surgical oncology · 2025

Genomic and Clinical Predictors of Conversion in Initially Unresectable Colorectal Cancer Liver Metastases.

Zuo Daocheng, Wang Lu, Jin Kangpeng, Zhang Yue, Wang Yaping, Sun Yueming, Tang Junwei

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Colorectal cancer liver metastases (CRLM) present significant treatment challenges, requiring multimodal conversion therapies. Identifying factors that influence treatment outcomes is crucial for improving clinical management.

PATIENTS AND

METHODS

This retrospective cohort study included 286 patients with synchronous CRLM who underwent conversion therapies on the basis of sequencing results. Patients were categorized into successful conversion therapy group (SCTG) and failed conversion therapy group (FCTG). Clinical factors and genomic mutations were analyzed for associations with therapy outcomes and survival.

RESULTS

Among the patients, 106 (37.1%) achieved successful conversion (SCTG), while 180 (62.9%) failed (FCTG). Compared with SCTG, patients in the FCTG had significantly larger metastatic lesions, higher preoperative mesenteric lymph node positivity, and elevated carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels. Six genes (FAT, BRAF, SERPINA3, GRIN2A, ERBB2, and ALK) showed the highest mutation frequency differences in FCTG, correlating with worse outcomes. Any of these mutations was associated with shorter overall survival compared with wild-type patients. A nomogram model using tumor mutation status, CEA, CA19-9, lesion diameter ≥ 5 cm, and positive lymph nodes at diagnosis predicted conversion efficacy (area under the curve = 89.6, 95% confidence interval 22.6-92.4). An extended conversion-related clinical risk score scoring system incorporating these factors effectively stratified poor prognosis populations, serving as a prognostic tool for patients with unresectable CRLM.

CONCLUSIONS

Genomic profiling improves precision management of CRLM, facilitating tailored conversion strategies and better prognostic prediction. Future studies should validate these findings in prospective cohorts to refine personalized treatment for patients with initially unresectable CRLM.

Для цитирования: Zuo Daocheng, Wang Lu, Jin Kangpeng, Zhang Yue, Wang Yaping, Sun Yueming, Tang Junwei. Genomic and Clinical Predictors of Conversion in Initially Unresectable Colorectal Cancer Liver Metastases.. Annals of surgical oncology. 2025. DOI: 10.1245/s10434-025-17809-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.